The Winship Cancer Institute Clinical Trials Office (Winship CTO) is a shared resource of the Winship Cancer Institute that supports clinical research by providing centralized management and support of resources to conduct high-quality clinical trials involving cancer patients. The Winship CTO manages the overall process of clinical trial conduction, including subject screening, consent, registration, data entry, and regulatory document submission for clinical research studies involving cancer patients. This is accomplished by fulfilling the following six objectives: 1. To provide infrastructure support for the development and implementation of human clinical research protocols relevant to cancer. 2. To provide the disease management teams with administrative support to facilitate subject screening, consent, registration, study-specific tests and treatments, response and toxicity assessment, and data entry. 3. To provide the cancer disease-site teams with regulatory support to ensure compliance with Good Clinical Practice, the IRB, FDA, and other regulatory agencies. 4. To monitor overall accrual of subjects on therapeutic and non-therapeutic cancer-related clinical trials and provide support for the Winship Executive Director and leaders of the research programs in monitoring accrual to specific protocols. 5. To provide education and training for staff and faculty involved in clinical research. 6. To disseminate information on active clinical trials involving cancer patients to the Emory community and patients and referring physicians in Georgia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138292-05
Application #
8520246
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
5
Fiscal Year
2013
Total Cost
$148,003
Indirect Cost
$53,130
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Richardson, Alessandra M; Havel, Lauren S; Koyen, Allyson E et al. (2018) Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin Cancer Res 24:420-432
Goldstein, Jordan S; Nastoupil, Loretta J; Han, Xuesong et al. (2018) Disparities in survival by insurance status in follicular lymphoma. Blood 132:1159-1166
Guidot, Daniel M; Switchenko, Jeffrey M; Nastoupil, Loretta J et al. (2018) Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59:888-895
Jin, Lingtao; Chun, Jaemoo; Pan, Chaoyun et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell 34:315-330.e7
Chowdhary, Mudit; Okwan-Duodu, Derick; Switchenko, Jeffrey M et al. (2018) Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. J Neurooncol 136:289-298
Chen, Zhengjia; Zheng, Youyun; Wang, Zhibo et al. (2018) Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. Contemp Clin Trials Commun 12:145-153
Halani, Sameer H; Yousefi, Safoora; Vega, Jose Velazquez et al. (2018) Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. NPJ Precis Oncol 2:24
Ferris, Matthew J; Liu, Yuan; Ao, Jingning et al. (2018) The addition of chemotherapy in the definitive management of high risk prostate cancer. Urol Oncol 36:475-487
Halicek, Martin; Little, James V; Wang, Xu et al. (2018) Deformable Registration of Histological Cancer Margins to Gross Hyperspectral Images using Demons. Proc SPIE Int Soc Opt Eng 10581:
Cassidy, Richard J; Switchenko, Jeffrey M; El-Deiry, Mark W et al. (2018) Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas. Laryngoscope :

Showing the most recent 10 out of 331 publications